| Name | Title | Contact Details |
|---|
Formed by revenue cycle industry leaders, Currance is a Rev-Cycle Performance solutions company focused on empowering community providers, physician practices and healthcare systems to achieve and sustain yield performance improvement. Currance`s strategy of Performance Partnering supports your own team by offering everything needed to drive yield performance: an intelligent technology platform that integrates with existing systems, tailored solutions, and professional services for operationalizing the technology and sustaining exceptional results. The Currance approach encompasses best-in-class knowledge of revenue cycle management, proprietary technologies, and the proven ability to engage, train, and mentor employees, adding value to clients` organizations. We embrace a mindset rooted in science and operational experience, enabling highly efficient processes and precise workflow design that improve profitability and help build patient-centered, high-performing organizations.
Mitchell County Hospital Health Systems is a regional hospital located in Beloit, Kansas that serves North Central Kansas patients and communities with exceptional healthcare in a compassionate and healing environment.
PCHS of Alaska (Peninsula Community Health Services) is a Soldotna, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.
Patients vary in more ways than gender, race, and size. At Conformis, we believe that optimizing implant fit and performance requires a patient-specific approach. Our mission is to provide best-in-class, patient-specific implants and instrumentation that offer unique advantages over traditional orthopedic implants. We start with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. Our implants are individually sized and shaped to fit to each patient`s unique anatomy, providing precise anatomic fit and preserving healthy tissue. Our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. By combining our personalized implants with our unique instrumentation, a surgeon is able to provide a custom solution that preserves more of a patient`s joint and minimizes surgical trauma. Conformis, Inc. is a privately held medical device company based in Massachusetts. It was founded in 2004 to provide dramatic advancements in patient care by utilizing imaging technology to create personalized, patient-specific implants and instrumentation.